StockNews.AI
GDRX
StockNews.AI
173 days

GoodRx Reports Fourth Quarter and Full Year 2024 Results

1. GoodRx reports Q4 2024 revenue of $198.6 million with net income of $6.7 million. 2. Adjusted net income margin is 17.5%, indicating strong profitability potential.

Earnings
-1.33%Current Return
VS
-1.69%S&P 500
$4.8902/27 06:19 AM EDTEvent Start
$4.82502/28 01:16 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

GoodRx's financial results show growth in revenue and profitability. The increased net income and adjusted margins enhance investor confidence, reminiscent of positive trends seen in similar tech healthcare firms like Teladoc Health following strong quarterly reports.

How important is it?

The article directly relates to GoodRx's latest financial performance, impacting investor sentiment and stock activity. As earnings influence stock valuations, the solid performance metrics could lead to increased stock interest.

Why Short Term?

The immediate market reaction is likely as investors digest the earnings report. Historically, strong quarterly results lead to short-term stock price upticks, as seen with companies like Peloton after reporting exceeding expectations.

Related Companies

TDOCAMGNCVS
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Revenue1 of $198.6 million Net income of $6.7 million; Net income margin of 3.4% Adjusted Net Income1 of $34.7 million; Adjusted Net Income Margin1 of 17.5% Adjusted EBITDA1 of $67.1 million; Adjusted EBITDA.

Related News